Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

THE BIOSIMILARS FORUM

Filed by THORN RUN PARTNERS.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-10-28 06:26:13 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
$100,000.00
Expenses
Not reported
Filing UUID
ae7e07f3-738f-4ec0-8373-f7c99f4b350a
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Medicare reimbursement issues. FDA regulations of biosimilars. Issues related to Drug Pricing Reduction and increasing access to Biosimilars. Inflation Reduction Act implementation. H.R.5526/S.1954 - Biosimilar Red Tape Elimination Act. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.

Literal federal measure citations: H.R.5526, S.1954, H.R.9661, S.1414

HCR · Health Issues

Drug pricing legislation. Labor, Health and Human Services issues. Efforts surrounding user fees. S.2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026. H.R.9661/S.1414 - Expedited Access to Biosimilars Act.

Literal federal measure citations: S.2256, H.R.9661, S.1414

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.